Why you need an integrated development plan
Learn about the Integrated Development Plan for successful drug development & its relation to the…
Certara2024 年 10 月 17 日
Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
Certara2024 年 9 月 23 日
Resmetirom: A pioneering NASH clinical program
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…
Certara2024 年 8 月 23 日
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
Certara2024 年 8 月 19 日
Medicines that matter: Biohaven’s Nurtec™ drug development journey
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…
Certara2024 年 8 月 15 日
Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies
靶向放射性核素治疗（TRT）通过将细胞毒性辐射选择性作用于肿瘤实现精准治疗。In recent years, oncology drug…
Certara2024 年 5 月 22 日
